Parkman Healthcare Partners LLC Purchases 24,839 Shares of NewAmsterdam Pharma Company N.V. $NAMS

Key Points

• Parkman Healthcare Partners LLC increased its stake in NewAmsterdam Pharma by 32.6% in the first quarter, acquiring an additional 24,839 shares, bringing its total holdings to 100,955 shares valued at approximately $2.07 million.
• The company reported a quarterly loss with an EPS of ($0.15), which exceeded analyst expectations of ($0.52) per share, alongside a revenue of $19.15 million compared to the anticipated $1.44 million.
• NewAmsterdam Pharma has received favorable ratings from multiple analysts, including a target price increase from Royal Bank of Canada from $38.00 to $39.00, and has a consensus rating of "Moderate Buy" with a price target of $41.55.

Parkman Healthcare Partners LLC lifted its stake in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) by 32.6% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 100,955 shares of the company's stock after acquiring an additional 24,839 shares during the period. Parkman Healthcare Partners LLC owned approximately 0.09% of NewAmsterdam Pharma worth $2,067,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Barclays PLC boosted its stake in NewAmsterdam Pharma by 120.0% in the 4th quarter. Barclays PLC now owns 16,713 shares of the company's stock worth $429,000 after purchasing an additional 9,117 shares during the period. The Manufacturers Life Insurance Company purchased a new stake in shares of NewAmsterdam Pharma in the fourth quarter worth about $221,000. Northern Trust Corp bought a new position in shares of NewAmsterdam Pharma in the fourth quarter valued at approximately $556,000. Schonfeld Strategic Advisors LLC purchased a new position in NewAmsterdam Pharma during the fourth quarter valued at approximately $524,000. Finally, BNP Paribas Financial Markets bought a new stake in NewAmsterdam Pharma during the 4th quarter worth approximately $916,000. 89.89% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have recently commented on NAMS. The Goldman Sachs Group initiated coverage on shares of NewAmsterdam Pharma in a research report on Thursday, July 17th. They set a "neutral" rating and a $27.00 price target for the company. Wells Fargo & Company started coverage on NewAmsterdam Pharma in a research note on Monday, August 25th. They set an "overweight" rating and a $45.00 price objective for the company. Royal Bank Of Canada upped their target price on NewAmsterdam Pharma from $38.00 to $39.00 and gave the stock an "outperform" rating in a research note on Thursday, August 7th. Needham & Company LLC reaffirmed a "buy" rating and issued a $40.00 price target on shares of NewAmsterdam Pharma in a report on Thursday, June 12th. Finally, Wall Street Zen raised NewAmsterdam Pharma from a "sell" rating to a "hold" rating in a report on Saturday, July 5th. Nine investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $41.55.

Insider Buying and Selling at NewAmsterdam Pharma

In other news, COO Douglas F. Kling sold 51,043 shares of the company's stock in a transaction on Wednesday, July 16th. The shares were sold at an average price of $21.10, for a total value of $1,077,007.30. Following the completion of the sale, the chief operating officer owned 44,000 shares of the company's stock, valued at approximately $928,400. This represents a 53.71% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director James N. Topper bought 1,260 shares of the firm's stock in a transaction that occurred on Monday, September 8th. The stock was acquired at an average price of $24.99 per share, for a total transaction of $31,487.40. Following the transaction, the director owned 3,027,864 shares in the company, valued at $75,666,321.36. This trade represents a 0.04% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders have bought 14,095 shares of company stock valued at $279,621 and have sold 424,954 shares valued at $9,773,906. 20.84% of the stock is currently owned by insiders.

NewAmsterdam Pharma Price Performance

NASDAQ NAMS traded down $0.30 during trading hours on Thursday, reaching $26.60. 2,254,819 shares of the stock traded hands, compared to its average volume of 893,073. The stock has a 50 day simple moving average of $23.45 and a two-hundred day simple moving average of $20.70. NewAmsterdam Pharma Company N.V. has a 1 year low of $14.06 and a 1 year high of $27.35. The company has a market cap of $3.00 billion, a price-to-earnings ratio of -16.42 and a beta of -0.01.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.15) earnings per share for the quarter, beating analysts' consensus estimates of ($0.52) by $0.37. The company had revenue of $19.15 million for the quarter, compared to analysts' expectations of $1.44 million. NewAmsterdam Pharma had a negative return on equity of 27.27% and a negative net margin of 259.07%. On average, sell-side analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current fiscal year.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.